Kukje Pharma
Seongnam-si Gyeonggi-do (HQ)
Financials
Estimates*
| KRW | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenues | 123.3b | 107.7b | 111.1b | 130.4b | 119.7b | 126.6b | 135.4b |
| % growth | - | (13 %) | 3 % | 17 % | (8 %) | 6 % | 7 % |
| EBITDA | 5.2b | 6.0b | 8.8b | 9.7b | 2.7b | 9.8b | 2.2b |
| % EBITDA margin | 4 % | 6 % | 8 % | 7 % | 2 % | 8 % | 2 % |
| Profit | 1.1b | 2.2b | (4.8b) | 2.2b | (1.6b) | 3.6b | (8.4b) |
| % profit margin | 1 % | 2 % | (4 %) | 2 % | (1 %) | 3 % | (6 %) |
| EV / revenue | 1.0x | 0.9x | 1.0x | 1.6x | 1.2x | 1.0x | 1.0x |
| EV / EBITDA | 23.1x | 16.1x | 12.1x | 21.8x | 51.4x | 13.2x | 63.2x |
| R&D budget | - | - | - | 3.0b | 2.8b | 2.0b | 2.6b |
| R&D % of revenue | - | - | - | 2 % | 2 % | 2 % | 2 % |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
| Total Funding | - | ||
